PT  - JOURNAL ARTICLE
AU  - Martin Bauer
AU  - Matthias Blaickner
AU  - Cécile Philippe
AU  - Wolfgang Wadsak
AU  - Marcus Hacker
AU  - Markus Zeitlinger
AU  - Oliver Langer
TI  - Whole-Body Distribution and Radiation Dosimetry of <sup>11</sup>C-Elacridar and <sup>11</sup>C-Tariquidar in Humans
AID  - 10.2967/jnumed.116.175182
DP  - 2016 Aug 01
TA  - Journal of Nuclear Medicine
PG  - 1265--1268
VI  - 57
IP  - 8
4099  - http://jnm.snmjournals.org/content/57/8/1265.short
4100  - http://jnm.snmjournals.org/content/57/8/1265.full
SO  - J Nucl Med2016 Aug 01; 57
AB  - 11C-elacridar and 11C-tariquidar are new PET tracers to assess the transport activity of P-glycoprotein (adenosine triphosphate–binding cassette subfamily B, member 1 [ABCB1]) and breast cancer resistance protein (adenosine triphosphate–binding cassette subfamily G, member 2 [ABCG2]). This study investigated the whole-body distribution and radiation dosimetry of both radiotracers in humans. Methods: Twelve healthy volunteers (6 women, 6 men) underwent whole-body PET/CT imaging over the 90 min after injection of either 11C-elacridar or 11C-tariquidar. Radiation doses were calculated with OLINDA/EXM software using adult reference phantoms. Results: Biodistribution was consistent with a major elimination route of hepatobiliary excretion, which may be mediated by ABCB1 and ABCG2. High radioactivity uptake was seen in liver, followed by spleen and kidneys, whereas brain uptake was lowest. Effective doses were 3.41 ± 0.06 μSv/MBq for 11C-elacidar and 3.62 ± 0.11 μSv/MBq for 11C-tariquidar. Conclusion: Our data indicate that both 11C-elacridar and 11C-tariquidar are safe radiotracers, for which an injected activity of 400 MBq corresponds to a total effective dose of approximately 1.5 mSv.